Core Viewpoint - The pension funds have actively invested in the secondary market, appearing in the top ten circulating shareholders of nine stocks by the end of the third quarter, with six new entries and two increased holdings [1][2]. Group 1: Pension Fund Holdings - By the end of the third quarter, pension accounts held a total of 103 million shares across nine stocks, with a combined market value of 3.281 billion yuan [1]. - The largest holding was in Haiyou Development, with pension funds holding 65.3843 million shares, making them the ninth and fourth largest shareholders [1]. - The second largest holding was in Guoyao Shares, with 20.318 million shares held by pension funds, ranking as the fourth largest shareholder [1]. Group 2: Stock Performance and Changes - Among the stocks held by pension funds, four had a market value exceeding 100 million yuan, including Chuncheng Power, Guoyao Shares, and Haiyou Development [1]. - The stock with the highest net profit growth in the third quarter was Dingtong Technology, achieving a net profit of 176.572 million yuan, a year-on-year increase of 125.39% [3]. - The pension fund's longest-held stock is Chuncheng Power, which has appeared in the top ten shareholders for 14 consecutive reporting periods, maintaining a holding of 7.9514 million shares [2]. Group 3: Sector Distribution - The pension fund's holdings are distributed across different boards, with five stocks on the main board, one on the Sci-Tech Innovation Board, and three on the Growth Enterprise Market [3]. - The pension fund's holdings include stocks from various industries, such as oil and petrochemicals, pharmaceuticals, automotive, basic chemicals, telecommunications, electronics, mechanical equipment, beauty care, and construction decoration [3].

Core Viewpoint - The company, Keta Bio, announced the receipt of three patent certificates from the National Intellectual Property Administration, indicating progress in its intellectual property portfolio [2] Group 1 - Keta Bio and its wholly-owned subsidiary, Inner Mongolia Keta Bio Co., Ltd., have recently received three patent certificates [2]

Core Insights - The company reported a revenue of 104,043,568.35 yuan for the third quarter of 2025, representing a year-on-year growth of 28.98% [2] - The net profit attributable to shareholders of the listed company was 35,026,934.69 yuan, showing a year-on-year increase of 26.56% [2] Financial Performance - Revenue for Q3 2025: 104,043,568.35 yuan, up 28.98% year-on-year [2] - Net profit for Q3 2025: 35,026,934.69 yuan, up 26.56% year-on-year [2]

Core Viewpoint - The company reported a year-on-year increase in revenue and net profit for the third quarter, indicating positive growth trends in its financial performance [1] Financial Performance - The company's operating revenue for the first three quarters reached 267 million, representing a year-on-year growth of 22.25% [1] - The net profit attributable to shareholders for the same period was 76.23 million, showing a year-on-year increase of 7.08% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 67.08 million, reflecting a year-on-year growth of 9.79% [1]

Core Viewpoint - The company reported a revenue increase of 22.25% year-on-year for the first three quarters of 2025, indicating strong growth in its financial performance [1] Financial Performance - The company's operating revenue for the first three quarters reached 267 million yuan [1] - Net profit attributable to shareholders was 76.232 million yuan, reflecting a year-on-year growth of 7.08% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 67.078 million yuan, with a year-on-year increase of 9.79% [1] - Basic earnings per share stood at 0.29 yuan [1]

Group 1 - The company, Keta Bio, announced on October 21 that its 15th meeting of the third board of directors was held via communication voting on October 20, 2025 [1] - The meeting reviewed documents including the proposal for the third quarter report of 2025 [1] Group 2 - The article highlights the need to shift funding focus from excessive investment in housing and infrastructure to enhancing investment in the livelihood sector [1]

证券代码：300858 证券简称：科拓生物 公告编号：2025-044 北京科拓恒通生物技术股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京科拓恒通生物技术股份有限公司（以下简称"公司"或"科拓生物"） 及全资子公司内蒙古科拓生物有限公司（以下简称"内蒙科拓"）于近期收到国 家知识产权局颁发的 3 项专利证书，具体情况如下： | 序号 | 发明名称 | 专利号 | 专利权人 | 专利 类型 | 申请日期 | 授权日期 | 证书号 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 一种用于预防和/或治 疗糖尿病性视网膜病 变和保护视力的鼠李 糖乳酪杆菌及其后生 | ZL202410 843371.X | 科拓生物 | 发明专 利 | 2024-6-27 | 2025-10-3 | 第 8331799 | 号 | | | 元制品和应用 干酪乳杆菌 在 Zhang | | | | | | | | | 2 | 制备治疗皮肤病的制 | ZL20 ...

Group 1 - The core viewpoint of the article highlights the financial performance of Keta Bio, reporting a revenue of approximately 267 million yuan for the first three quarters of 2025, representing a year-on-year increase of 22.25% [1] - The net profit attributable to shareholders of the listed company is approximately 76.23 million yuan, reflecting a year-on-year increase of 7.08% [1] - The basic earnings per share is reported at 0.29 yuan, which is a year-on-year increase of 7.41% [1]

证券代码：300858 证券简称：科拓生物 公告编号：2025-042 2、本次会议于 2025 年 10 月 20 日以通讯表决方式进行。 3、本次会议应出席董事 7 人，实际出席董事 7 人。 4、本次董事会由董事长孙天松女士召集和主持，公司高级管理人员列席了 本次董事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《北京科拓恒通生物技术股份有限公司章程》的有关规定，会议合法、 有效。 二、董事会会议审议情况 北京科拓恒通生物技术股份有限公司 第三届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、北京科拓恒通生物技术股份有限公司（以下简称"公司"）第三届董事会 第十五次会议通知于 2025 年 10 月 17 日以邮件通知方式向各位董事发出，同时 列明了会议的召开时间、内容和方式。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 三、备查文件 1、《北京科拓恒通生物技术股份有限公司第三届董事会第十五次会议决议》； 2、《北京科拓恒通生物技术股份有限公司第三届董事 ...

北京科拓恒通生物技术股份有限公司 2025 年第三季度报告 证券代码：300858 证券简称：科拓生物 公告编号：2025-043 北京科拓恒通生物技术股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： □是 否 1 北京科拓恒通生物技术股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 104,043,568.35 | 28.98% | 267,389,193.46 | 22.25% | | 归属于上市公司股东 | 35,026,934.69 | 26.56% | 76,231,997.73 | 7.08% | | 的净利润（元） | | | | | | 归属于上市公司股东 的扣除非经常性损益 | 31, ...